Learn about ZETO and explore a whole new world of EEG.
Read case studies from Dr. Virginia Thornley and Joe Charles of JLC Services to learn more about our EEG headset’s applications. Visit our FAQ page for more on Zeto’s next gen EEG headset.
Zeto is a medical technology startup transforming the way EEG (Electroencephalography) is done at hospitals. They are solving a problem that has remained unsolved since EEG was invented in 1924, that is, an archaic, tedious approach that consumes time, requires a trained technician and puts the patient through a poor experience. This FDA approved wireless device is zero-prep, easy to wear headset with dry electrodes backed by a digital platform that offers instant upload, tools for analysis and remote interpretation by neurologists. Ena Sarkar meets the team and learns about this big disrupt in healthcare that opens new significant opportunities for conditions such as Epilepsy, Stroke, Concussion and Sleep disorders.
Read case studies from Dr. Virginia Thornley and Joe Charles of JLC Services to learn more about our EEG headset’s applications. Visit our FAQ page for more on Zeto’s next gen EEG headset.
Zeto EEG provides a better, more convenient EEG testing experience to patients and technicians and faster turnaround time to hospitals than current technology
SANTA CLARA, Calif., May 29, 2018 /PRNewswire/ — Zeto, Inc., a privately held medical technology company transforming the way electroencephalography (EEG) is done at hospitals, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its dry electrode EEG headset, called zEEG, for use in the clinical setting. The zEEG is the first FDA approved dry electrode EEG headset backed by a cloud platform that offers instant upload, tools for analysis and remote interpretation by neurologists.
“EEG is a critically important test for evaluation of patients with seizures or unexplained confusion that might be due to subtle seizures. Unfortunately, EEG technology has not evolved much since its inception almost 100 years ago, leaving EEG underutilized for neurological conditions,” said Robert S. Fisher, M.D., Ph.D., Director of the Stanford Epilepsy Center and former President of the American Epilepsy Society. “The zEEG technology will allow diagnosis and testing in hospitals and clinics that could not previously perform EEGs. This will be a very significant advance.”
“With the approval of zEEG, healthcare professionals and patients now have access to an EEG system that provides a simple, easy and convenient experience with the benefit of quick and smart analysis of data through our cloud platform,” said Aswin Gunasekar, MS, MBA, Chief Executive Officer and Founder of Zeto, Inc. “Our goal was to find a technology that would not only democratize access to EEG with a seamless platform but also unlock the potential of AI, opening up significant opportunities for conditions such as epilepsy, stroke, concussion and sleep disorders. We are proud to have developed a solution that presents a paradigm shift for EEG.”
A clinical study demonstrated that the zEEG headset provided EEG signal quality that was comparable to an approved, traditional EEG system. 30 patients in two study cohorts (EEG patients and healthy volunteers) were studied for specific time periods (up to 2 hours), and the zEEG was found to perform at least as well as the reference device based on predefined acceptance criteria. Study results will be published in the coming months.
“This approval is particularly meaningful to the Epilepsy Foundation, since the zEEG system was selected as the winner of the 2016 Epilepsy Foundation Shark Tank and was also awarded a New Therapy Commercialization Investment in 2017,” said Jacqueline French MD, Chief Scientific Officer of the Epilepsy Foundation and Professor of Neurology, NYU Langone Health’s Comprehensive Epilepsy Center. “We saw a great potential for the electroencephalogram, an old diagnostic technique, to take a great leap into the modern age, making it more accessible for diagnosis of epilepsy.”
The FDA approved the Zeto EEG system in April 2018. Zeto plans to continue working with leading hospital beta customers in preparation for a commercial launch later in the year.
About Zeto, Inc.
Zeto, Inc. is a privately held medical technology company located in Santa Clara, CA focused on transforming the way electroencephalography (EEG) is done at hospitals. Zeto’s revolutionary platform brings the traditional EEG procedure to the 21st century by offering zEEG, a zero-prep, wireless, easy-to-wear headset with 19 dry electrodes that can be positioned as per the 10-20 EEG system, backed by a cloud platform that offers instant upload, tools for analysis and remote interpretation by neurologists. The company plans to leverage its platform technology to improve access and affordability to brain wave testing and achieve better outcomes for neurological conditions such as epilepsy, stroke, concussion and sleep disorders, among others.
Congratulations to Zeto and its CEO/Founder Aswin Gunasekar. The FDA has recently approved their product for clinical use. Zeto’s “dry electrode” headset, is the first of its kind to obtain FDA approval, enables doctors to obtain EEGs quickly and conveniently to 10-20 EEG specifications. The easy-use cloud platform makes EEG available to any health care facility.
In April 2018, the U.S. Food and Drug Administration (FDA) approved Zeto, Inc.’s “dry electrode” EEG (electroencephalogram) headset and its software platform for clinical use.
The Zeto headset, called zEEG, is easy to wear and does not need any preparation.
The EEG data collected from the headset is sent wirelessly to a cloud platform. This means the EEG is sent and stored using the internet.
The doctor or health care provider reading the EEG can view it live and read or interpret what the EEG means very quckily.
The dry electrode headset gives accurate 10-20 EEG placement and records EEG data consistent with the typical EEG.
“This approval is particularly meaningful to the Epilepsy Foundation, since the Zeto EEG system was selected as a prize winner in the 2016 Epilepsy Foundation Shark Tank. It was also awarded a New Therapy Commercialization Grant in 2017,” said Jacqueline French MD, chief scientific officer of the Epilepsy Foundation and professor of neurology, NYU Langone Health’s Comprehensive Epilepsy Center. “We saw a great potential for the EEG, an old diagnostic technique, to take a great leap into the modern age, making it more accessible for diagnosis of epilepsy.”
Source – https://www.epilepsy.com/learn/diagnosis/eeg/dry-electrode-headset-eeg
The mission of the Epilepsy Therapy Project of the Epilepsy Foundation is to accelerate ideas into new therapies for people living with epilepsy and seizures.
Zeto is developing a turnkey solution for Routine EEG tests by providing EEG to facilities that do not have access to train EEG operators or neurologists. The goal of Zeto is to have a system that satisfies the following:
Aswin Gunasekar, founder of Zeto Inc., presents his team’s instant EEG project at the 2016 Epilepsy Foundation Shark Tank competitionntries around the world.
Read case studies from Dr. Virginia Thornley and Joe Charles of JLC Services to learn more about our EEG headset’s applications. Visit our FAQ page for more on Zeto’s next gen EEG headset.
The Epilepsy Foundation’s Shark Tank competition seeks to advance innovative ideas in epilepsy and seizure treatment and care. The winners will use their prize to accelerate their innovation to the next phase of development and closer to being accessible to people living with epilepsy.
In total, 65 individuals or teams entered the “Shark Tank” competition from across the U.S. and 13 countries around the world.